
==== Front
Drugs Real World Outcomes
Drugs Real World Outcomes
Drugs - Real World Outcomes
2199-1154
2198-9788
Springer International Publishing Cham

39102100
443
10.1007/s40801-024-00443-0
Original Research Article
Enhancing Outcomes in Chronic Fibrotic Interstitial Lung Disease Through Aggressive Management of Nintedanib-Induced Adverse Drug Reactions: A Retrospective Analysis
Chang Yu-Wen 1
Tsai Meng-Yun 2
Chang Yu-Ping 2
Liao Chien-Chang 3
Lin Yu-Ting 4
Lai Chien-Hao 2
Lin Meng-Chih 25
http://orcid.org/0000-0002-8363-8151
Huang Kuo-Tung jelly@cgmh.org.tw

25
1 https://ror.org/00k194y12 grid.413804.a Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
2 https://ror.org/02verss31 grid.413801.f 0000 0001 0711 0593 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, No. 123, Dapi Rd., Niaosong Dist., Kaohsiung, Taiwan, ROC
3 grid.145695.a 0000 0004 1798 0922 Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan
4 https://ror.org/00k194y12 grid.413804.a Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
5 grid.413801.f 0000 0001 0711 0593 Chang Gung Respirology Center of Excellence, Taipei, Taiwan
5 8 2024
5 8 2024
9 2024
11 3 521527
16 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Background and Objectives

Nintedanib, a tyrosine kinase inhibitor, is integral in slowing pulmonary fibrosis progression in chronic fibrotic interstitial lung disease (ILD). However, the occurrence of adverse drug reactions (ADRs) often limits its use, leading to treatment discontinuation, typically within 3–12 months. Discontinuation adversely affects patient outcomes. The study investigated whether aggressive ADR management can prolong nintedanib therapy and improve patient outcomes.

Methods

This retrospective, single-center study enrolled Taiwanese patients with chronic fibrotic ILD who were treated with nintedanib from January 2016 to December 2022 in Kaohsiung Chang Gung Memorial Hospital. Patients were categorized into those who discontinued treatment within 180 days and those continuing beyond. Management of ADRs was identified through concurrent prescriptions for symptoms such as nausea, vomiting, diarrhea, or hepatic dysfunction. Baseline demographics, comorbidities, pulmonary function tests, and instances of acute exacerbation were analyzed.

Results

The study enrolled 94 patients, with 71 (75.5%) experiencing ADRs. Among these, 41 (43.6%) discontinued nintedanib within 180 days. The administration of medications for managing nausea/vomiting [17 (41.5%) versus 36 (67.9%), p = 0.0103] and diarrhea [12 (29.3%) versus 33 (62.3%), p = 0.0015] was less frequent in the discontinued group compared with the continued group. Additionally, a higher incidence of acute exacerbation was observed in the discontinued group (34.1% versus 20.8%, p = 0.016).

Conclusion

Aggressive management of ADRs may enhance patient tolerance to nintedanib, potentially prolonging treatment duration and improving outcomes in chronic fibrotic ILD.

issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmcKey Points

1. Higher incidence rate of ADRs was noted in the discontinued group.	
2. Medications for ADRs were significantly less frequently prescribed in the discontinued group.	
3. Aggressive management of ADRs may help patients tolerate nintedanib prolonging the duration of management and improving outcomes in chronic fibrotic ILD.	

Introduction

Interstitial lung diseases (ILDs) encompass a diverse group of diffuse parenchymal lung disorders that share similar clinical presentations and lung injury patterns. Idiopathic pulmonary fibrosis (IPF) is the predominant chronic fibrotic ILD and is a progressive disease characterized by deteriorating lung function and early mortality [1, 2]. Nintedanib is a tyrosine kinase inhibitor that targets key pathways involved in fibrotic ILDs and is approved for treating IPF [3–6], systemic sclerosis-associated ILD (SSc-ILD) [7], and progressive fibrosing interstitial lung disease (PF-ILD) [8]. Nintedanib has been shown to slow disease progression in IPF, PF-ILD, and SSc-ILD, potentially reducing the risks of lung function decline, acute exacerbations, and respiratory hospitalizations.

Adverse reactions (ADRs) to nintedanib usually involve the gastrointestinal system (e.g., nausea, vomiting, and diarrhea) or liver. Dose adjustments, temporary interruptions, and discontinuation of treatment can be necessary to eliminate these ADRs [3–8]. In the INPULSIS-ON study, nintedanib exhibited an acceptable safety and tolerability profile even over a long period (63 months), although safety concerns led to treatment discontinuation in approximately 10% of the included patients [9]. In a study involving patients with SSc-ILD, patients receiving nintedanib reported a higher incidence of common ADRs [8] than did those not receiving nintedanib.

The prescribing information for nintedanib includes recommendations for the management and monitoring of ADRs, which may include symptom treatment, dose adjustment, or discontinuation of treatment [10]. Given the limited availability of effective ILD treatments, discontinuing nintedanib could lead to rapid disease progression and reduced quality of life. Therefore, aggressively managing ADRs is warranted to prolong the duration of nintedanib use. However, this assumption lacks evidence and requires further investigation.

Methods

Study Design, Population, and Group Classifications

This study is a retrospective analysis conducted in a single center- Kaohsiung Chang Gung Memorial Hospital. Taiwanese patients aged ≥ 18 years with chronic fibrotic ILD who underwent nintedanib treatment between January 2016 and December 2022 were included. Diagnoses were reassessed in multidisciplinary discussions, and patients who were deemed to in fact not have chronic fibrotic ILD were excluded. Patients were excluded if they had a diagnosis of liver cirrhosis, chronic hepatitis, liver function impairment, or an active gastrointestinal tract disorder before receiving nintedanib or if they received any other antifibrotic agents.

Demographic characteristics, body surface area (BSA), body mass index (BMI), smoking history, comorbidities, fibrosis severity, results of pulmonary function tests, high-resolution computed tomography (HRCT) patterns, and instances of acute exacerbation for each patient were obtained from electronic medical records. Acute exacerbations were defined based on the consensus [11, 12].

Information regarding the prescription, interruption, or permanent discontinuation of nintedanib and the management of ADRs, such as the use of domperidone, mosapride, loperamide, silymarin, or ursodeoxycholic acid, was obtained from the database of hospital pharmacy attached to the medical center. Patients were divided into discontinued and continued groups depending on whether they discontinued nintedanib within 180 days.

Ethical approval for this study was obtained from the Institutional Review Board of Chang Gung Medical Foundation (IRB no.: 202201260B0 and 202201284B0). The study was performed in accordance with the standards of ethics outlined in the Declaration of Helsinki.

Statistical Analysis

Data are expressed as mean ± standard deviation unless otherwise stated. Categorical variables were analyzed using the chi-squared test or Fisher’s exact test, as appropriate. Continuous variables were compared using Student’s t-test or the Mann–Whitney U-test. The multiple logistic regression analysis with stepwise model selection was used to identify potential risk factors associated with nintedanib discontinuation. The regression model included the following variables: age in 10-year increments, gender, BSA (< 1.58 or ≥ 1.58 m2), GAP stage, smoking history, underlying fibrotic ILD (IPF or SSc-ILD), advanced ILD, chronic respiratory disease, and the requirement for additional medication to manage ADRs (nausea/vomiting and diarrhea). Stepwise regression was performed and covariates with a 0.1 significance level entered the model, while a 0.05 significant level was required to stay in the model.. Data analysis was performed using IBM SPSS software version 21.0. A two-sided p value of < 0.05 was considered statistically significant.

Results

In this study, 97 patients undergoing nintedanib therapy were identified from the database of hospital pharmacy. Following multidisciplinary discussions, three patients were excluded, leaving a total of 94 patients, comprising 78 with IPF and 16 with SSC-ILD (Fig. 1).Fig. 1 Study flow chart. MMD Multidisciplinary discussions, ILD Interstitial lung disease

Patient baseline characteristics are presented in Table 1. The mean age was 70.7 years, with 34 (36.2%) of the patients being older than 75 years. Most patients (n = 67, 71.3%) were men, and 57 (60.6%) patients had a history of smoking. The most common radiological finding on HRCT was a usual interstitial pneumonia pattern (88.3%). Patients were categorized into gender, age, and physiology (GAP) stages, with 27 (28.7%), 45 (47.9%), and 22 (23.4%) patients being categorized into stages I, II, and III, respectively. Advanced ILD [defined as diffusing capacity of the lung for carbon monoxide (DLco) ≤ 35% or forced vital capacity (FVC) ≤ 50%] was present in 22 (23.4%) patients, and 39 (41.5%) patients had chronic respiratory disease. Inhaled medications, including long-acting bronchodilators (LABA), long-acting muscarinic antagonists (LAMA), and inhaled corticosteroids, were prescribed for 67 (71.3%) patients, and 46(48.9%) patients undergoing oral corticosteroid therapy at baseline. Nintedanib was initiated at a low starting dose in 5 (5.3%) patients. Acute exacerbation within 12 months occurred in 25 (26.6%) patients. Table 1 Basic characteristics of the study population.

Characteristics	All (n = 94)	Discontinued group (n = 41)	Continued group (n = 53)	p-value	
Age, years	70.7 ± 9.9	72.3 ± 9.9	69.5 ± 9.9	0.1759	
< 75 years	60 (63.9)	25 (61.0)	35 (66.0)	0.6125	
≥ 75 years	34 (36.2)	16 (39.0)	18 (34.0)		
Sex					
 Female	27 (28.7)	15 (36.6)	12 (22.6)	0.1384	
 Male	67 (71.3)	26 (63.4)	41 (77.4)		
BMI (kg/m2)	23.1 ± 3.9	23.0 ± 3.1	23.1 ± 4.4	0.8988	
BSA (m2)	1.6 ± 0.2	1.6 ± 0.2	1.6 ± 0.2	0.0852	
 < 1.58	66 (70.2)	22 (53.7)	44 (83.0)	0.0842	
 ≥ 1.58	28 (29.8)	19 (46.3)	9 (17.0)		
Smoking history					
 Never	38 (40.4)	17 (41.5)	31 (58.5)	0.1015	
 Current/former	56 (59.65)	24 (58.54	22 (41.5)		
Fibrotic ILD					
 IPF	78 (83.0)	33 (80.5)	45 (84.9)	0.5719	
 SSC-ILD	16 (17.0)	8 (19.5)	8 (15.1)		
HRCT pattern					
 UIP	83 (88.3)	34 (82.9)	49 (92.5)	0.1542	
 Others	11 (11.7)	7 (17.1)	4 (7.5)		
GAP index				0.0408	
 Stage I (0–3)	27 (28.7)	12 (29.3)	13 (24.5)		
 Stage II (4–5)	45 (47.9)	15 (36.5)	32 (60.4)		
 Stage III (6–8)	22 (23.4)	14 (34.2)	8 (15.1)		
 Advanced ILDa	22 (23.4)	7 (17.1)	15 (28.3)	0.2023	
 Chronic respiratory diseaseb	39 (41.5)	14 (34.2)	25 (47.2)	0.2038	
 Inhaled medicine	67 (71.3)	29 (70.7)	38 (71.7)	0.3642	
 LAMA alone	6 (6.4)	4 (9.8)	2 (3.8)		
 LABA + LAMA	38 (40.4)	14 (34.2)	24 (45.3)		
 LABA + ICS	12 (12.8)	4 (9.8)	8 (15.1)		
 LABA + LAMA + ICS	11 (11.7)	7 (17.1)	4 (7.6)		
Oral corticosteroidc	51 (54.3)	19 (46.3)	32 (60.4)	0.1942	
 Starting dose of nintedanib, n (%)					
 300 mg/day	89 (94.7)	39 (95.1)	50 (94.3)	0.8669	
 < 300 mg/day	5 (5.3)	2 (4.9)	3 (5.7)		
 Acute exacerbation during follow-up, n (%)	25 (26.6)	14 (34.1)	11 (20.8)	0.0160	
Values are displayed as number (%), mean ± standard deviation

BMI body mass index, BSA body surface area, DLco diffusion capacity of carbon monoxide, FVC forced vital capacity, GAP gender–age–physiology, ICS inhaled corticosteroid, ILD interstitial lung disease, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist

aDLco pred ≤ 35% or FVC pred ≤ 50%

bChronic obstructive pulmonary disease or asthma

cBaseline using oral steroid before nintedanib management

Baseline characteristics between the discontinued and continued groups displayed no significant differences, except in the incidence of acute exacerbations (34.1% versus 20.8%, p = 0.0160) and GAP index (p = 0.0408; Table 1). FVC (% of predicted value) and DLco (% of predicted value) remained stable within the first 180 days and exhibited no significant differences between the two groups (Table 2). Table 2 Pulmonary function test at baseline, 24 weeks and difference between 0 and 24 weeks

	All (n = 94)	Discontinued group (n = 41)	Continued group (n = 53)	p-value	
FVC, % of predicted value, baseline	69.2 ± 19.9	69.3 ± 17.3	69.2 ± (15.1)	0.9893	
Category, n (%)					
 < 70%	46 (48.9)	22 (53.7)	25 (47.2)	0.5327	
 ≥ 70%	48 (51.1)	19 (46.3)	28 (52.8)		
 < 50%	9 (9.6)	5 (12.2)	4 (7.5)	0.4476	
 ≥ 50%	85 (90.4)	36 (87.8)	49 (92.5)		
 < 50%	9 (9.6)	5 (12.2)	4 (7.6)	0.4725	
 ≥ 50% and < 80%	64 (68.1)	29 (70.7)	35 (66.0)		
 ≥ 80%	21 (22.3)	7 (17.1)	14 (26.4)		
FVC, % of predicted value, at 24 weeks	66.7 ± 16.3	65.4 ± 14.9	67.5 ± 17.0	0.6539	
Change FVC between 0 and 24 weeks	− 1.7 ± 8.6	− 1.3 ± 1.5	− 0.1 ± 1.0	0.5076	
FEV1,% of predicted value, at baseline	76.1 ± 17.1	78.3 ± 18.0	74.5 ± 16.3	0.2900	
FEV1,% of predicted value, at 24 weeks	73.4 ± 17.8	74.5 ± 16.7	73.0 ± 18.4	0.7824	
DLco, % of predicted value, at baseline	48.0 ± 15.5	51.3 ± 14.4	46.0 ± 15.9	0.1711	
DLco, % of predicted value, at 24 weeks	44.3 ± 15.9	42.0 ± 32.1	45.1 ± 39.0	0.5866	
Change DLco between 0 and 24 weeks	− 0.7 ± 9.2	− 4.0 ± 6.4	0.47 ± 9.8	0.1724	
Values are displayed as number (%), mean ± standard deviation

DLco diffusion capacity of carbon monoxide, FEV1 forced expiratory volume in one second, FVC forced vital capacity

ADRs were experienced by 71 (75.5%) patients, with a higher incidence in the discontinued group (82.9% versus 69.8%, p = 0.0132; Table 3). Five patients in the discontinued group died, with their deaths suspected to be due to ADR-related sepsis. ADR-related dose reductions occurred in 14 (14.9%) patients, and 24 (25.5%) needed to discontinue nintedanib. Most discontinuations (23.4%) were temporary, but two patients in the discontinued group permanently stopped treatment. Medical therapy for ADRs, such as nausea/vomiting, diarrhea, and hepatitis, was prescribed in both groups. Medications specifically for nausea/vomiting, and diarrhea were significantly less frequently prescribed in the discontinued group compared with the continued group. The figures were 17 (41.5%) and 12 (29.3%) in the discontinued group versus 36 (67.9%) and 33 (62.3%) in the continued group for nausea/vomiting and diarrhea, respectively (p = 0.0103 and 0.0015, respectively; Table 3). Table 3 Adverse drug reactions and the medication for ADRs in the study groups

	All (n = 94)	Discontinued group (n = 41)	Continued group (n = 53)	p-value	
Any ADRs	71 (75.5)	34 (82.9)	37 (69.8)	0.0132	
ADRs leading to:					
 Death	5 (5.3)	5 (12.2)	0	< 0.0001	
 Lost follow-up	8 (8.5)	4 (9.8)	4 (7.6)	0.6715	
 Dose reduction	14 (14.9)	5 (12.2)	9 (17.0)	0.6864	
 Discontinuation	24 (25.5)	17 (41.5)	7 (13.2)	< 0.0001	
 Temporary	22 (23.4)	15 (36.6)	7 (13.2)	< 0.0001	
 Permanent	2 (2.1)	2 (4.9)	0 (0)	0.0453	
Medication for ADRs:					
 For nausea/vomiting	53 (56.4)	17 (41.5)	36 (67.9)	0.0103	
 For diarrhea	45 (47.9)	12 (29.3)	33 (62.3)	0.0015	
 For hepatic dysfunction	21 (22.3)	8 (19.5)	13 (24.5)	0.5626	
Values are displayed as number (%)

ADR adverse drug reactions

Multivariable analysis considered potential factors influencing discontinuation (each 10-year age increase, BSA < 1.58 m2, GAP index, and medications for ADRs; Table 4). Older age (in 10-year increments) and low BSA (< 1.58 m2) were independently associated with discontinuation. A lower GAP index (stage II versus III) and aggressive medication management for ADRs were associated with less discontinuation (Table 4). Table 4 Multivariate analysis of factors associated with discontinuation of nintedanib

Variables	Univariable	Multivariable	
OR (95% CI)	p-value	OR (95% CI)	p-value	
Age in years, 10-year increments	1.851 (1.049–3.013)	0.0365	1.562 (1.011–3.262)	0.0449	
Gender (F versus M)	2.172 (0.960–5.019)	0.0650			
BSA, (< 1.58 m2 versus ≥ 1.58 m2)	2.172 (1.160–6.019)	0.0253	2.660 (1.198–7.205)	0.0343	
GAP stage, (I versus III)	0.581 (0.179–1.834)	0.8727			
GAP stage, (II versus III)	0.289 (0.102–0.781)	0.0188	0.203 (0.059–0.622)	0.0072	
Smoking history (never versus current/former)	0.503 (0.219–1.135)	0.1006			
Fibrotic ILD (IPF versus SSc-ILD)	1.671 (0.743–3.814)	0.2171			
Advanced ILD (N versus Y)	1.186 (0.528–2.677)	0.6802			
Chronic respiratory disease (without versus with)	1.533 (0.682–3.487)	0.3033			
Medication for ADRs:					
For nausea/vomiting	0.321 (0.136–0.735)	0.0081	0.302 (0.110–0.779)	0.0154	
For diarrhea	0.266 (0.111–0.615)	0.0024	0.226 (0.082–0.582)	0.0028	
ADR adverse drug reactions, BSA body surface area, GAP gender–age–physiology.

Discussion

This study highlights the importance of aggressive management ADRs in enhancing patient tolerance to nintedanib, prolonging the duration of management, and improving outcomes for those with chronic fibrotic ILD.

Our findings align with relevant clinical trials and real-world studies that show a high incidence of ADRs [3–,10,13–15]. Notably, Asian patients appear to experience ADRs at a higher rate compared with their counterparts in Europe and the USA [16–24]; the reasons for this discrepancy are unclear. Efforts to reduce ADRs are crucial for enhancing drug tolerability and maximizing long-term benefits for patients receiving nintedanib. Early intervention is key to reducing drug discontinuation. Although our study did not find an association between baseline or 24-week FVC and DLco levels and nintedanib discontinuation (Table 2), a deterioration in FVC was observed in a Japanese study [15] when nintadanib was discontinued within 3 months. This aligns with several studies indicating that early discontinuation of nintedanib is associated with a higher risk of acute exacerbation [3–8], a finding also supported by our study (Table 1). Patients discontinuing nintedanib within 180 days had a higher risk of acute exacerbations.

The primary ADRs associated with nintedanib include nausea, vomiting, diarrhea, and hepatic dysfunction [3–10, 13–15], each of which can negatively affect the nutritional status of patients. Japanese real-world data [15] indicated that a BSA of less than 1.58 m2 was associated with early discontinuation of nintedanib within 3 months. Our study corroborates these findings, indicating the necessity for strategies to counteract the nutritional effects. These gastrointestinal ADRs also reduce the willingness of patients to continue nintedanib, thereby influencing their compliance and adherence. Although our study associated ADR management with continued nintedanib use, direct evidence linking aggressive ADR management to enhanced drug toleration and patient compliance remains limited and requires further investigation. Notably, this association applies to all ADRs except for those related to hepatic dysfunction. This study is among the first to explore this concept, although further prospective investigations are warranted to confirm these findings and provide stronger evidence.

The INPULSIS-ON study [9] revealed that patients who continued nintedanib beyond 52 weeks rarely discontinued it due to diarrhea, suggesting that longer treatment durations may enhance tolerance to ADRs and improve patient outcomes. Our data, alongside the INPULSIS-ON study results, reinforce the necessity of optimal care for patients on nintedanib. Aggressive management of ADRs contributes to the continued use of nintedanib and superior patient outcomes.

Limitations

Our study demonstrates the advantages of early intervention in managing ADRs, which aids in maintaining the continuity of nintedanib treatment. However, acknowledging the study’s limitations is crucial. These include the study being retrospective, conducted at a single center, involving a relatively small patient cohort, and lacking detailed data on the incidence and severity of nausea, vomiting, diarrhea, and hepatic dysfunction. Additionally, the study lacks information on the severity of acute exacerbations and the incidence rate of acute exacerbation is notably high although similar results were observed [25, 26].

Conclusions

Our study underscores the significance of aggressive management of ADRs in helping patients tolerate nintedanib, thereby prolonging the duration of management and improving outcomes in chronic fibrotic ILD. The findings suggest that further prospective studies are necessary to validate these observations and to provide more comprehensive insights into this area of treatment.

Abbreviations

ADRs Adverse drug reactions

BMI Body mass index

BSA Body surface area

DLco Diffusing capacity of the lung for carbon monoxide

FVC Forced vital capacity

ILDs Interstitial lung diseases

IPF Idiopathic pulmonary fibrosis

PF-ILD Progressive fibrosing interstitial lung disease

SSc-ILD Systemic sclerosis-associated ILD

Declarations

Funding

This study did not receive financial support from any public, commercial, or nonprofit funding agencies.

Conflict of Interest

The authors have no conflicts of interest to declare.

Ethics Approval

Ethical approval for this study was obtained from the Institutional Review Board of Chang Gung Medical Foundation (IRB no.: 202201260B0 and 202201284B0). The study was performed in accordance with the standards of ethics outlined in the Declaration of Helsinki.

Consent to Participate

We anonymized the data retrospectively. Taiwan medical ethics guidelines do not require informed consent be obtained for this type of research.

Consent for Publication

Not applicable.

Data Availability

Data will be made available on reasonable request.

Code Availability

Not applicable.

Author Contributions

Yu-Wen Chang: Data collection, Statistic analysis and Manuscription. Meng-Yun Tsai: Data collection, Statistic analysis and Manuscription. Yu-Ping Chang: Data collection. Chien-Chang Liao: Data collection, multidisciplinary discussions. Yu-Ting Lin: Data collection, multidisciplinary discussions. Chien-Hao Lai: Data collection, multidisciplinary discussions. Meng-Chih Lin: Study design and consultation, multidisciplinary discussions. Kuo-Tung Huang: Study design and consultation, multidisciplinary discussions, and Corresponding author.
==== Refs
References

1. Travis WD Costabel U Hansell DM King TE Jr Lynch DA Nicholson AG An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias Am J Respir Crit Care Med 2013 188 6 733 748 10.1164/rccm.201308-1483ST 24032382
Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.24032382 10.1164/rccm.201308-1483ST
2. Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100.
3. Richeldi L du Bois RM Raghu G Azuma A Brown KK Costabel U Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 2014 370 22 2071 2082 10.1056/NEJMoa1402584 24836310
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.24836310 10.1056/NEJMoa1402584
4. Richeldi L Cottin V du Bois RM Selman M Kimura T Bailes Z Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials Respir Med 2016 113 74 79 10.1016/j.rmed.2016.02.001 26915984
Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med. 2016;113:74–9.26915984 10.1016/j.rmed.2016.02.001
5. Richeldi L Kreuter M Selman M Crestani B Kirsten AM Wuyts WA Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: Results from the TOMORROW trial and its open-label extension Thorax 2018 73 6 581 583 10.1136/thoraxjnl-2016-209701 28993537
Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: Results from the TOMORROW trial and its open-label extension. Thorax. 2018;73(6):581–3.28993537 10.1136/thoraxjnl-2016-209701
6. Richeldi L Costabel U Selman M Kim DS Hansell DM Nicholson AG Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N Engl J Med 2011 365 12 1079 1087 10.1056/NEJMoa1103690 21992121
Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87.21992121 10.1056/NEJMoa1103690
7. Distler O Highland KB Gahlemann M Azuma A Fischer A Mayes MD Nintedanib for systemic sclerosis-associated interstitial lung disease N Engl J Med 2019 380 26 2518 2528 10.1056/NEJMoa1903076 31112379
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–28.31112379 10.1056/NEJMoa1903076
8. Flaherty KR Wells AU Cottin V Devaraj A Walsh SLF Inoue Y Nintedanib in progressive fibrosing interstitial lung diseases N Engl J Med 2019 381 18 1718 1727 10.1056/NEJMoa1908681 31566307
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27.31566307 10.1056/NEJMoa1908681
9. Crestani B Huggins JT Kaye M Costabel U Glaspole I Ogura T Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON Lancet Respir Med 2019 7 1 60 68 10.1016/S2213-2600(18)30339-4 30224318
Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60–8.30224318 10.1016/S2213-2600(18)30339-4
10. US Food & Drug Administration, label OFEV (nintedanib). September 2019. Reference ID 4572087.
11. Collard HR Ryerson CJ Corte TJ Jenkins G Kondoh Y Lederer DJ Lee JS Maher TM Wells AU Antoniou KM Behr J Brown KK Cottin V Flaherty KR Fukuoka J Hansell DM Johkoh T Kaminski N Kim DS Kolb M Lynch DA Myers JL Raghu G Richeldi L Taniguchi H Martinez FJ Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report Am J Respir Crit Care Med 2016 194 3 265 275 10.1164/rccm.201604-0801CI 27299520
Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ. Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265–75.27299520 10.1164/rccm.201604-0801CI
12. Luppi F Sebastiani M Salvarani C Bendstrup E Manfredi A Acute exacerbation of interstitial lung disease associated with rheumatic disease Nat Rev Rheumatol 2022 18 2 85 96 10.1038/s41584-021-00721-z 34876670
Luppi F, Sebastiani M, Salvarani C, Bendstrup E, Manfredi A. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol. 2022;18(2):85–96.34876670 10.1038/s41584-021-00721-z
13. Song JW Ogura T Inoue Y Xu Z Quaresma M Stowasser S Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON Respirology 2020 25 4 410 416 10.1111/resp.13647 31329360
Song JW, Ogura T, Inoue Y, Xu Z, Quaresma M, Stowasser S, et al. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON. Respirology. 2020;25(4):410–6.31329360 10.1111/resp.13647
14. Cheng SL, Sheu CC, Chian CF, Hsu JY, Kao KC, Hang LW, et al. NICEFIT–A prospective, non-interventional, and multicentric study for the management of idiopathic pulmonary fibrosis with antifibrotic therapy in Taiwan. Biomedicines. 2022;10(10):2362.
15. Ogura T Inoue Y Azuma A Homma S Kondoh Y Tanaka K Real-world safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Interim report of a post-marketing surveillance in Japan Adv Ther 2023 40 4 1474 1493 10.1007/s12325-022-02411-y 36692681
Ogura T, Inoue Y, Azuma A, Homma S, Kondoh Y, Tanaka K, et al. Real-world safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Interim report of a post-marketing surveillance in Japan. Adv Ther. 2023;40(4):1474–93.36692681 10.1007/s12325-022-02411-y
16. Kato M Sasaki S Tateyama M Arai Y Motomura H Sumiyoshi I Clinical significance of continuable treatment with nintedanib over 12 months for idiopathic pulmonary fibrosis in a real-world setting Drug Des Devel Ther 2021 15 223 230 10.2147/DDDT.S284819 33500614
Kato M, Sasaki S, Tateyama M, Arai Y, Motomura H, Sumiyoshi I, et al. Clinical significance of continuable treatment with nintedanib over 12 months for idiopathic pulmonary fibrosis in a real-world setting. Drug Des Devel Ther. 2021;15:223–30.33500614 10.2147/DDDT.S284819
17. Yoon HY Park S Kim DS Song JW Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Respir Res 2018 19 1 203 10.1186/s12931-018-0907-8 30340638
Yoon HY, Park S, Kim DS, Song JW. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):203.30340638 10.1186/s12931-018-0907-8
18. Dobashi M Tanaka H Taima K Itoga M Ishioka Y Shiratori T The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: a multicenter retrospective study SAGE Open Med 2021 9 20503121211023357 10.1177/20503121211023357 34164129
Dobashi M, Tanaka H, Taima K, Itoga M, Ishioka Y, Shiratori T, et al. The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: a multicenter retrospective study. SAGE Open Med. 2021;9:20503121211023356.34164129 10.1177/20503121211023357
19. Toellner H Hughes G Beswick W Crooks MG Donaldson C Forrest I Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres Clin Transl Med 2017 6 1 41 10.1186/s40169-017-0172-3 29101500
Toellner H, Hughes G, Beswick W, Crooks MG, Donaldson C, Forrest I, et al. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clin Transl Med. 2017;6(1):41.29101500 10.1186/s40169-017-0172-3
20. Antoniou K, Markopoulou K, Tzouvelekis A, Trachalaki A, Vasarmidi E, Organtzis J, et al. Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Res. 2020;6(1):00172–2019.
21. Bonella F Kreuter M Hagmeyer L Neurohr C Keller C Kohlhaeufl MJ Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis Respiration 2016 92 2 98 106 10.1159/000448288 27544537
Bonella F, Kreuter M, Hagmeyer L, Neurohr C, Keller C, Kohlhaeufl MJ, et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration. 2016;92(2):98–106.27544537 10.1159/000448288
22. Galli JA Pandya A Vega-Olivo M Dass C Zhao H Criner GJ Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions Respirology 2017 22 6 1171 1178 10.1111/resp.13024 28317233
Galli JA, Pandya A, Vega-Olivo M, Dass C, Zhao H, Criner GJ. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology. 2017;22(6):1171–8.28317233 10.1111/resp.13024
23. Tzouvelekis A Karampitsakos T Kontou M Granitsas A Malliou I Anagnostopoulos A Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: a real-life observational study in Greece Pulm Pharmacol Ther 2018 49 61 66 10.1016/j.pupt.2018.01.006 29366978
Tzouvelekis A, Karampitsakos T, Kontou M, Granitsas A, Malliou I, Anagnostopoulos A, et al. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: a real-life observational study in Greece. Pulm Pharmacol Ther. 2018;49:61–6.29366978 10.1016/j.pupt.2018.01.006
24. Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, et al. Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Res. 2018;4(4):00049–2018.
25. Huang TH Kuo CW Chen CW Tseng YL Wu CL Lin SH Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study BMC Pulm Med 2021 21 1 165 10.1186/s12890-021-01530-6 33992083
Huang TH, Kuo CW, Chen CW, Tseng YL, Wu CL, Lin SH. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study. BMC Pulm Med. 2021;21(1):165.33992083 10.1186/s12890-021-01530-6
26. Tseng CM Chen MY Kao CY Tao CW Investigation of clinical predictors of survival in idiopathic pulmonary fibrosis patients: a cohort study in Taiwan J Chin Med Assoc 2022 85 5 578 583 10.1097/JCMA.0000000000000719 35353790
Tseng CM, Chen MY, Kao CY, Tao CW. Investigation of clinical predictors of survival in idiopathic pulmonary fibrosis patients: a cohort study in Taiwan. J Chin Med Assoc. 2022;85(5):578–83.35353790 10.1097/JCMA.0000000000000719
